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 ABSTRACT  
AQUEOUS RAFT POLYMERIZATION OF GLYCOPOLYMERS FOR PEPTIDE 
INTERACTION STUDIES AND ANTIMICROBIAL PEPTIDE MIMICS FOR 
ANTIMICROBIAL ACTIVITY AND SELECTIVITY STUDIES 
by Sarah Elizabeth Exley 
May 2015 
 The first section of this work describes the synthesis and characterization of novel 
glycopolymers synthesized to model GM1 gangliosides, a glycolipid found in neuronal 
cells.  Glucose and galactose were attached to N-hydroxyethyl acrylamide, using 
chemistry that granted control over the stereochemistry at the C1’ carbon of each 
saccharide, and polymerized via aqueous RAFT (aRAFT).  Homopolymers, targeting 
either 30 or 300 DP, and copolymers, with N-dimethyl acrylamide, were prepared as a 
glycopolymer platform for investigation of amyloid β (Aβ), a naturally occurring peptide 
associated with Alzheimer’s disease, aggregation.  Aβ aggregation kinetics and aggregate 
size in the presence of glycopolymer were determined. 
 The second section of this work describes N-(3-guanadinopropyl)methacrylamide 
(GPMA) synthesis, homopolymerization and copolymerization with N-(3-aminopropyl) 
methacrylamide (APMA) using aRAFT.  Many naturally occurring AMPs have an 
abundance of lysine and arginine. GPMA, an arginine mimic, was incorporated into our 
established acrylamide based antimicrobial peptide (AMP) platform with APMA, a lysine 
mimic, to increase the activity and selectivity of our AMPs over a wider range of 
bacteria.  Antimicrobial activity, against E. coli, S. aureus, and P. aeruginosa, and 
selectivity, against human red blood cells and cancer cells, was determined for the 
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GPMA and APMA homopolymers and copolymers.  The effect of GPMA counterion on 
activity and selectivity was also investigated.  
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CHAPTER I 
INTRODUCTION 
 This dissertation focuses on the synthesis and testing of polymers that mimic 
GM1 gangliosides and antimicrobial peptides.  In Chapters II and III, the attachment of 
glucose and galactose to an acrylamide backbone, with specific β stereochemistry at C1’, 
will be described.  The homopolymerization and copolymerization, with N, N-
dimethylacrylamide, of the synthesized glucose and galactose monomers using aqueous 
RAFT polymerization will also be discussed.  Aggregation of amyloid β peptides in the 
presence of the reported polymers will be conferred.  Chapters IV and V will investigate 
the synthesis of a methacrylamide monomer with a guanidinium pendant group.  This 
monomer as well as a methacrylamide with a primary amine will be polymerized into 
homopolymers and statistical copolymers via aqueous RAFT polymerization.  These 
polymers will then be tested for effective bacterial activity and selectivity.  
 Aqueous RAFT (aRAFT) will be used to synthesize polymers with precise 
molecular weights and compositions to allow systematic investigations.  aRAFT is an 
ideal technique for the development of saccharide- and amine-containing polymers with 
specific distributions, as it is compatible with a wide range of monomers, enables control 
of molecular weight and polydispersity, allows for a wide range of polymer 
conformations to be synthesized, and does not require extreme protection/deprotection of 
substituent groups.  Additionally, aRAFT can be performed under aqueous conditions 
and, unlike other controlled polymerization techniques, is unaffected by charged species, 
maintaining control throughout the reaction.  
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 In both projects, either an acrylamide or methacrylamide is utilized as the 
polymer backbone.  This was done to impart the desirable chemical attributes of 
acrylamides/methacrylamides onto our synthetic platforms.  Specifically, we designed 
polymers with acrylamide backbones to increase their hydrolytic stability and solubility.  
The antimicrobial peptide testing was done at physiological pH (pH 7.4); however, the 
Aβ investigation was done at pH 8, and the increased stability and solubility of the 
acrylamide backbone eliminates hydrolysis and precipitation concerns, respectively.  
Additionally, both projects are designed as platforms for future research, therefore, 
having an acrylamide/methacrylamide backbone will allow for a more diverse 
implementation of the developed systems.   
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CHAPTER II 
GLYCOPOLYMER ARCHITECTURES 
Chapter Overview 
 This chapter aims to inform the reader of pertinent literature pertaining to the 
aggregation of amyloid β (Aβ) peptides in response to the saccharides of GM1 
gangliosides, providing the argument and need for the research presented in Chapter III.  
Briefly, Aβ peptides are implicated in the pathology of Alzheimer’s disease, as they are 
present in the extracellular space of neuronal cells as soluble oligomers or insoluble 
fibrils that lead to plaque formation.  Through interaction with various modulators, Aβ 
peptides are shown to undergo conformational change and aggregate into toxic species.  
GM1 gangliosides are reported as modulators that increase and alter Aβ aggregation.  The 
head group of GM1 gangliosides are comprised of several saccharide residues, including 
glucose and galactose.  Efforts have been made to identify the specific influence of 
glucose and galactose on Aβ aggregation; however, it is difficult to separate the effects of 
the individual saccharides using traditional biochemical techniques.  Circumventive 
methods, used to evaluate saccharide contribution, resulted in conflicting reports.  
Finally, polymer research has not demonstrated soluble biorelevant glycopolymers that 
are stable over a wide range of testing conditions nor used them to evaluate saccharide 
impact on Aβ aggregation. 
Important Literature 
 Alzheimer’s disease (AD) is a neurodegenerative disease that is responsible for 
approximately 70% of all dementia cases.1  Elucidation of the pathology of AD is 
important as it will provide the opportunity for treatment development.  AD is 
  
characterized by the progressive degeneration of cognitive and ambulatory abilities and 
the development of intricate neuropatholo
neurons and the appearance of senile plaques and neurofibrillary tangles (NFTs).
senile plaques are formed from amyloid fibrils, which are a result of the aggregation of 
the peptide amyloid-β (Aβ
originate from cleavage of
peptides are Aβ40 and Aβ
1).4  Aβ42 is thought to be the more toxic of
present study.3-4  Aβ aggregates via self
form larger molecular weight oligomers and fibrils.
Figure 1. Illustrations detailing the amino acid residues and their corresponding 
or charge of Aβ monomer. Hydrogen bonding occurs at residues 22, glutamic acid, and 
28, lysine, stabilizing the monomer in a 
 Various studies have determined that the soluble oligomeric species 
peptides are the result of an aggregation pathway discrete from that of fibrillogenesis or 
amyloidogenesis.  Gellerman 
but interchange between the two aggregate species does not occur, indicating that each 
 
 
gical features,2 namely significant loss of 
).  Aβ is expressed in the extracellular space of the brain 
 the amyloid precursor protein (APP).  The most prevalent 
42, having 40 and 42 amino acid residues, respectively
 the species, and is thus the focus of the 
-association in a nucleation-dependent manner to 
  
β sheet conformation. 
et al. determined that not only are the pathways discrete, 
4 
3
  The 
and 
 (Figure 
 
polarity 
of Aβ 
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are stable entities.2  Previous studies in our laboratories demonstrated a similar 
phenomenon, indicating that two different aggregation pathways exist.5  Each aggregate 
species promotes further conformational change and aggregation of monomeric Aβ42 
(i.e. like promotes like).2 
 The toxicity of Aβ fibrils are widely debated as there seems to be a 
disproportionate association between the appearance of fibril plaques and the extent of 
neurological damage.  That is, the brains of people suffering from AD impairment have 
varying concentrations of fibril plaques, and the plaque level does not directly correlate 
with the degree of impairment.5  Additionally, Williams et al. determined that the greater 
the degree of association of the peptide, meaning the more fibril-like it became, the less 
effective it was as a membrane disruptor, with membrane disruption being one potential 
cause of neuronal cell death.2  This lack of correlation suggests that the oligomeric 
species play a significant role in AD pathology.  
 Various modulators have been demonstrated to promote conformational changes 
and aggregation of Aβ peptides.  Gangliosides are glycosphingolipids that are composed 
of a hydrophobic ceramide, consisting of a sphingosine and a fatty acid moiety, 
hydrophilic sugars and sialic acid moieties (Figure 2).3  Gangliosides are found 
throughout the brain in varying concentrations.  The fraction of GM1 gangliosides has 
been reported to comprise 0.5-13% w/w of the membrane.  With increasing age, the GM1 
fraction increases to 15-30% w/w of the membrane.  Additionally, cholesterol 
concentrations in the cell membrane increase with age and promote aggregation and lipid 
raft formation of GM1 gangliosides.  Increase in ganglioside concentration, both locally 
through lipid rafts and globally through increased ganglioside number, is thought to 
6 
 
 
 
 
promote the shift of common non-toxic monomeric Aβ species to toxic aggregate 
species.6  Yanagisawa et al. discovered that GM1-bound Aβ peptides are present during 
early stages of AD pathogenesis and it is hypothesized that the peptides act as “seeds” to 
polymerize Aβ into mature fibrils and senile plaques.7  Choo-Smith et al. observed that 
Aβ40 interacted with micellar GM1-gangliosides and as a result of the interaction, Aβ40 
underwent a conformational change characterized by a conformational change from 
randomly coiled to cross β-sheet structure.8  The hydrophobic, apolar C-terminal region 
of Aβ40 was suggested to be paramount for interaction with GM1-gangliosides.  The 
authors hypothesized that Aβ interaction with gangliosides could induce membrane 
perturbation that ultimately leads to neuronal cell death.8-9  Recently, however, 
Yamamoto et al. determined that different variants of Aβ peptides bind to different types 
of gangliosides;10 though, the reason has yet to be fully understood.  The primary 
differences between the various types of gangliosides are the types and distributions of 
saccharides present in the hydrophilic head group and the number of sialic acid moieties 
present.  Sialic acids have been extensively studied and their affects are known.11  
Therefore, the preferential binding of the variant Aβ peptides to specific gangliosides 
must result from the different types and distributions of saccharides present within each 
respective ganglioside. 
  
Figure 2. An illustration of GM1 ganglioside, with all components appropriately labelled.
 To date, little has been accomplished to elucidate the influence of individual 
saccharides on the aggregation mechanisms of A
simple carbohydrates on the aggregation and fibrillogenesis of A
secondary and quaternary conformational changes in relation to the presence of 
individual saccharides.12 
glucose and sucrose and that the hydrogen bonding pattern unique to each
crucial in the development of A
Aβ42 binding affinities as well as saccharide
aggregation through the development of self
saccharides, which were entitled sugar microarrays.
N-acetyl-β-D-glucosamine (
glucose (β-Glc), 6-sulfo-β
attached to a substrate through click chemistry.
strongest binding affinity towards 6
Glc, β-GlcNAc, and α-Man. 
 
 
β42.  Fung et al. studied the effect of 
β42 by observing 
 They concluded that the secondary structure was affected by 
β42 structure.  Matsumoto et al. analyzed saccharide
-induced peptide conformational change and 
-assembled monolayers (SAM
13
  The various saccharides, including 
β-GlcNAc), β-galactose (β-Gal), α-mannose (α
-D-glucosamine (6-sulfo-β-D-GlcNAc) and sialic acid were 
  It was determined that Aβ
-sulfo-β-D-GlcNAc followed by sialic acid, 
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 saccharide is 
-
s) of 
-Man), β-
42 had the 
β-Gal, β-
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 Synthesis of soluble glycomonomers and glycopolymers has been documented in 
the literature, though not for Aβ aggregation research.  We previously reported the 
attachment of D-glucuronic acid sodium salt to aminopropyl methacrylamide for 
polymerization via aRAFT.14  The addition was successful; however, this, like many 
other glyco-systems,15 utilized chemistries that remove a portion of the biological 
relevance, as the attachment of D-glucuronic acid sodium salt resulted in glycomonomer 
pendant to the polymer backbone through a nitrogen rather than an oxygen, and 
stereochemical control at C1’ was not obtained.  McCormick et al. reported kinetic data 
for the homopolymerization and chain extension of a methacrylate glycan monomer via 
aRAFT, using a dithioester chain transfer agent (CTA).15b  Ambrosi et al. reported the 
synthesis and the free radical polymerization of glucose and galactose functionalized 
methacrylates with retention of β stereochemistry at C1’.16  Parry et al. synthesized a 
methacrylamide glycan monomer that maintained α stereochemistry at C1’ and was 
polymerized via RAFT in a DMF:H2O mixture using a dithioester as the chain transfer 
agent.17  
 To our knowledge, the synthesis of acrylamide based glycomonomers with 
controlled stereochemistry at the C1’ carbon and their polymerization via aRAFT have 
not been previously reported.  Additionally, the effects of glucose and galactose on the 
aggregation of Aβ have not been clearly established.  Previous studies, using simple 
sugars and sugar microarrays, show contradictory results,12-13 and appropriate biorelevant 
concerns are not considered, such as (1) stereochemistry of the sugar to monomer 
attachment, and (2) concentration and localization of the representative saccharides.  
Finally, investigation of the aggregation processes of Aβ species formed in the presence 
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of soluble glycopolymers has not yet been reported.  In this paper, synthesis of galactose 
and glucose glycomonomers with an acrylamide backbone, is detailed, as well as the 
RAFT controlled homo- and co-polymerization of N-dimethyacrylamide, 2- (β-D-
galactosyloxy)ethyl acrylamide (GalEAm) and β-glucosyloxy)ethyl acrylamide 
(GlcEAm).  Aβ aggregation testing in the presence of glycopolymers, done through ThT 
fluorescence and SDS-PAGE is also described. 
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CHAPTER III 
EXPERIMETAL DETAIL FOR GLYCOPOLYMER ARCHITECTURES 
Research Overview 
 From previously reported results, it is clear that gangliosides present in the lipid 
bilayer of eukaryotic cells, when in sufficient concentrations, provoke aggregation of Aβ 
peptides.  Sialic acids as well as a ceramide tail are present in all gangliosides, leaving 
differences in saccharide moieties and distribution as the only differentiable 
characteristics between gangliosides.  Unfortunately, control over sugar chemistry in 
biomacromolecules is very difficult, with the isolation of a specific saccharide and 
saccharide distribution being nearly impossible utilizing traditional biochemical 
techniques.  To alleviate these difficulties, this project aimed to generate synthetic 
polymer models with glucose and galactose, as pendant groups, through the use of 
aRAFT controlled radical polymerization to develop a fundamental understanding of how 
Aβ peptides interact with saccharides on GM1 gangliosides.  aRAFT polymerization will 
be employed to achieve the specificity needed to properly evaluate the effects of 
saccharides.  The results from these studies will help to resolve the previously reported 
contradictory findings for Aβ peptide-saccharide aggregation.  In this chapter the 
synthesis of galactose and glucose glycomonomers with an acrylamide backbone, is 
detailed, as well as the RAFT controlled homo- and copolymerization of N-dimethyl 
acrylamide, 2- (β-D-galactosyloxy)ethyl acrylamide (GalEAm) and β-glucosyloxy)ethyl 
acrylamide (GlcEAm).  Aβ aggregation testing in the presence of glycopolymers, done 
through ThT fluorescence, and SDS-PAGE and immunoblotting, is also described. 
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Objectives of Research and Research Questions 
 This project aimed to develop a synthetic polymer platform that mimics the 
saccharide head groups of gangliosides for investigation into Aβ peptide aggregation and 
future saccharide related environmental questions.  The goal of this project was achieved 
through several research objectives and questions: 
I. Glycomonomers synthesized with correct stereochemistry at the C1’ carbon of 
either glucose or galactose.  
a. Can sufficient yield be obtained for the addition of HEAm to 
dehalogenated saccharide despite the inherent tendency for HEAm to 
retain water, which when present generates a competitive reaction?  
II. Glycomonomers polymerized into homo- and statistical copolymers, with N, 
N-dimethyl acrylamide via aqueous RAFT.  
a. Does the steric properties of the bulky saccharide affect the ability of 
RAFT to control the molecular weight and PDI when higher MW 
glycopolymers are targeted? 
b. Will copolymerization of the glycomonomers with DMA result in a 
statistical distribution of each monomer?  
III. Aβ peptides aggregation monitored in response to each (glyco)polymer and 
compared to Aβ peptides aggregation in environments free of (glyco)polymers 
and other aggregation affecting agents. 
a. Do our considerations for biorelevance result in a clear answer for the 
environmental effect of saccharides on Aβ peptides, resolving conflict in 
previous research? 
12 
 
 
 
 
b. Does the stereochemistry of the C4’ carbon, which separates glucose and 
galactose, provide enough of a change in environment to alter the 
aggregation of Aβ peptides? 
Materials and Methods 
Materials 
 For protected glycomonomer synthesis, acetobromo-α-galactose, ≥95% (AcGal) 
(Sigma-Aldrich, USA), acetobromo-α-glucose, ≥95% (AcGlc) (Sigma-Aldrich, USA), 
silver trifluoromethanesulfonate, >99% (silver triflate) (Sigma-Aldrich, USA), sodium 
sulfate, >99% anhydrous (Sigma-Aldrich, USA), and powdered 3Å molecular sieves 
(Sigma-Aldrich, USA) were used as purchased.  N-Hydroxyethyl acrylamide (HEAm) 
(Sigma-Aldrich, USA) was filtered through neutral aluminum oxide (Sigma-Aldrich, 
USA) to remove the inhibitor. Dichloromethane (DCM) (Sigma-Aldrich, USA) was 
distilled from calcium carbonate under nitrogen gas.  For glycomonomer deprotection, 
sodium methoxide, 30 wt% in methanol (Sigma-Aldrich, USA), methanol, 98.8% 
anhydrous (MeOH) (Sigma-Aldrich, USA), and Dowex® 50WX2 (Sigma-Aldrich, USA) 
were used as purchased.  Polymerization utilized sodium acetate, >99% anhydrous 
(Sigma-Aldrich, USA), and acetic acid, glacial (Fisher Scientific) for a 0.11M buffer 
(0.025 M acetic acid, 0.075 M sodium acetate).  N,N-Dimethylacrylamide (DMA) 
(Sigma-Aldrich, USA) was distilled, under vacuum, to remove the inhibitor.  
Additionally, 4,4’-Azobis(4-cyanovaleric acid), ≥98% (V-501) (Sigma-Aldrich, USA) 
was used as the initiator. 4-cyano-4-(ethylsulfanylthiocarbonylsulfanyl)pentanoic acid 
(CEP) was used as the chain transfer agent (CTA) and was synthesized via previously 
published procedures.18  For testing with Aβ peptides, Aβ 42 was synthesized by and 
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purchased from the Peptide Synthesis Facility at the Mayo Clinic (Rochester, MN) using 
routine Fmoc (N-(9-fluorenyl) methoxycarbonyl) chemistry.  MALDI-TOF mass 
spectrometry revealed >90% purity of the peptide.  Sodium dodecylsulfate (SDS) and 
thioflavin-T (ThT) were procured from Sigma-Aldrich (USA).  All other chemicals were 
obtained from VWR Inc. 
Synthesis of 2-(2’,3’,4’,6’-Tetra-O-acetyl-β-D-galactosyloxy)ethyl acrylamide 
(AcGalEAm) and 2-(2’,3’,4’,6’-Tetra-O-acetyl-β-D-glucosyloxy)ethyl acrylamide 
(AcGlcEAm).  
 Elimination of water was paramount for the successful synthesis of AcGalEAm 
and AcGlcEAm; therefore, all glassware was heated in an oven at 140°C for 30 minutes 
and cooled under nitrogen.  AcGal or AcGlc (26 g, 65 mmol) was added to a solution of 
HEAm (5 eq.) and 5% powdered molecular sieves in DCM (1000 mL), while stirring 
under nitrogen for one hour.  Silver triflate (1.5 eq.) was then added, maintaining a 
positive pressure of nitrogen, and then the mixture was allowed to stir for 24 hours 
(Scheme 1).  After addition of silver triflate, the positive pressure of nitrogen was 
removed and the reaction mixture was kept under closed conditions, maintaining an air 
free environment.  The appearance of a gray/purple sediment indicated the progress of the 
reaction, as silver bromide, a light sensitive byproduct, precipitated.  The final solution 
was filtered, washed with 1M HCl (3x), to remove excess HEAm, and dried over sodium 
sulfate.  Rotary evaporation and lyophilization resulted in a faintly peach colored solid 
(Yield: ~70%).  AcGalEAm, 1H NMR (300 MHz, DMSO): δ [ppm] 2.00, 2.06, 2.16 (d, 
m, m; 12H-m, n, o, p); 3.52 (m; 2H-e); 3.60, 3.75 (m, m; 1H-d, 1H-d); 3.92 (m; 1H-l); 
4.14 (m; 1H-k); 4.48 (m; 1H-k); 5.02 (d of d; 1H-j); 5.20 (m, 1H-g); 5.40 (t; 1H-h); 5.67 
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(d of d; 1H-a); 6.10 (m; 1H-b); 6.31 (m; 1H-C).  AcGlcEAm, 1H NMR (300 MHz, 
DMSO): δ [ppm] 2.06 (m, 12H-m, n, o, p); 3.56 (m, 2H-e); 3.73, 3.89 (m, m; 1H-d, 1H-
d); 4.14 (m, 1H-l); 4.24 (m; 1H-k); 4.52 (m; 1H-f); 4.99 (m; 1H-j); 5.10 (m, 1H-g); 5.22 
(m; 1H-h); 5.66 (d of d; 1H-a); 6.13 (m; 1H-b); 6.30 (m, 1H-c). 
 
 
Scheme 1. Synthesis of AcGalEAm.  The same conditions were employed to prepare 
AcGlcEAm. 
2- (β-D-galactosyloxy)ethyl acrylamide (GalEAm) 2- (β-D-glucosyloxy)ethyl acrylamide 
(GlcEAm).  
 AcGalEAm and AcGlcEAm were deacetylated by an established procedure.16  
Sodium methoxide (1 mL per 10 mL of solvent) was added to a solution of either 
AcGAlEAm or AcGlcEAm in methanol, while it stirred under nitrogen, and the mixture 
was allowed to react for 40 minutes (Scheme 2).  Dowex® 50WX2 was then added to the 
reaction mixture to absorb sodium cations and neutralize the solution and allowed to stir 
for 15 minutes.  A faintly peach colored, hygroscopic solid was obtained after filtration, 
rotary evaporation and lyophilization. GalEAm,  1H NMR (300 MHz, D2O): δ [ppm] 3.2-
  
3.8 (m; 10H-d’, e’, f’, g’, h’, i', h’, k’, l’); 4.20 (d, 1H
1H-c’, 1H-b’).  GlcEAm, 
g’, h’, i', h’, k’, l’); 4.27, 5.02 (d of d, d of d; (1H
c’, 1H-d’). 
 
Scheme 2. Deacetylation of AcGalEAm to form the desired monomer, GalEAm.  The 
same conditions were utilized to form GlcEAm.
Aqueous RAFT Polymerization of Glycopolymers. 
 Utilizing aqueous RAFT polymerization, polymer molecular weights were 
targeted by selecting appropriate initial monomer and CTA concentrations. 
M0:CTA0 was set to be approximately 
60% and 30%, to yield a degree of polymerization of ~
monomer concentration of the reaction was 0.5 M.
polymerizations targeting a DP of 300
at a ratio of CTA0:I0 of 5.
ratio of CTA0:I0 of 10.  The polymerization took plac
 
 
-f’); 5.56 (d of d; 1H
1H NMR (300 MHz, D2O): δ [ppm] 3.0-3.85 (m; 10H
-f’); 5.57 (d of d; 1H-a’); 6.0
 
 
500:1 and 100:1, with an expected conversion of 
300 and 30, respectively
 V-501 was used as the initiator.
, CEP was used as the chain transfer agent (CTA) 
  For polymerizations targeting a DP of 30, CEP was used at a 
e in 0.1 M sodium acetate buffer 
15 
-a’); 6.03 (m; 
-d’, e’, f’, 
4 (m; 1H-
 
 The ratio of 
.  The 
  For 
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(pH 5), with benzene sulfonic acid as an internal standard (25 mg), at 70°C.19  Methanol 
was added in low quantities (200 µL) to improve the solubility of CEP in the aqueous 
media (Scheme 3).  After the completion of the reaction, the solutions were quenched in 
liquid nitrogen and exposed to air.  Each solution was then dialyzed against water for 72 
hours, lyophilized for 72 hours and then stored in desiccant until testing.  For the purpose 
of this paper, polymers are referred to as either PGal or PGlc to identify homopolymers 
of GalEAm or GlcEAm, respectively.  The subscript number, as in PGal300, indicates the 
targeted degree of polymerization. 
 
 
Scheme 3. Representative aqueous RAFT polymerization of GalEAm.  Identical 
conditions were used for all homo- and copolymerizations. The CTA, on top of the 
reaction arrow, is CEP and the initiator, below the reaction arrow, is V-501. 
Nuclear Magnetic Resonance (NMR) 
 1H NMR was performed with a Varian MercuryPLUS 300 MHz spectrometer in 
CDCl3, utilizing delay times of 2 s to confirm monomer synthesis and identify the 
structures of PGal, and  PGlc homopolymers, and the PDMA-stat-PGal/PDMA-statPGlc 
copolymers.  64 scans were taken for each experiment with a 3.1 second recycle delay.  
For each of the homopolymers, unique peak assignments were made, and the copolymer 
compositions were calculated for the statistical polymer via peak integration.  1HNMR 
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was also performed on aliquots taken at intervals from reaction mixtures to monitor 
conversion and ensure linearity of monomer conversion with time.  Conversion was 
determined through comparative integration of the internal standard, benzene sulfonic 
acid, and the vinylic peaks.   
Mass Spectrometry 
 In order to determine the molecular weight of synthesized AcGalEAm (m/z: 445 
+ 23 (Na)), AcGlcEAm (m/z: 445 + 23 (Na)), GalEAm (m/z: 277 + 23 (Na)) and 
GlcEAm (m/z: 277 + 23 (Na)), mass spectroscopy was done on a ThermoFinnigan (San 
Jose, CA) TSQ 7000 triple-quadrapole instrument that was equipped with an electrospray 
ionization source (ESI).  The capillary temperature was maintained at a temperature of 
200°C, with a voltage of 20 V.  The electrospray needle voltage was 4.7 kV, and the tube 
lens was maintained between 70 and 100 V.  Samples were injected into the ESI source 
as a methanol/water (1:1) solution that had sodium chloride to charge the polymers.  The 
solutions were injected at a rate of 10 µL/sec.  All data was analyzed using Xcalibur 
(Fischer-Scientific, Inc.) software.   
Matrix-Assisted Laser Desorption Ionization (MALDI) Time of Flight Spectrometry  
  MALDI-ToF was used to determine the molecular weight and polydispersity of 
all synthesized glycopolymers.  All MALDI was done on a Bruker Microflex, equipped 
with a 337 nm nitrogen laser in linear mode and 20 kV accelerating voltage.  The detector 
gain was set at 5.0x. Pulsed ion extraction (800 ns and 360 ns for higher and lower MW 
polymers, respectively) was used during the collection of all data.  An average of 100 
laser shots was obtained for each polymer.  Two poly(styrene) standards, 4,000 g/mol and 
50,000 g/mol, were used as external calibration standards.  Plates were spotted using a 
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thin layer by layer deposition technique.  2,5-Dihydroxybenzoic acid (Sigma-Aldrich, 
USA), used as the matrix, was dissolve in HPLC grade THF (50 mg/mL) and then 
spotted onto the MALDI plate.  Prompt evaporation of THF, via blowing, was used to 
obtain small crystals.  Each glycopolymer was then dissolved in HPLC grade water (1 
mg/mL) and spotted on top of the dried DHB matrices.  A heat gun was used to promote 
rapid evaporation of water and create smaller glycopolymer crystals.    
Amyloid-β Peptide Isolation  
 Lyophilized stocks of synthetic Aβ 42 were stored at -20 °C desiccated.  Briefly, 
1.5–2 mg of peptide was dissolved in 0.5 ml of 30 mM NaOH and stored for 15 min at 
room temperature prior to size exclusion chromatography (SEC) onto a 1X30-cm 
Superdex-75 HR 10/30 column (GE Healthcare) attached to an ÄKTA FPLC system (GE 
Healthcare) to remove any preformed aggregates, as reported previously.20  The column 
was pre-equilibrated in 20 mM Tris-HCl (pH 8.0) at 25 °C and run at a flow rate of 0.5 
ml/min.  One-minute fractions were collected. Concentrations of Aβ were determined by 
UV-visible spectrometry on a Cary 50 spectrophotometer (Varian Inc.) using a molar 
extinction coefficient of 1450 cm-1 M-1 at 276 nm (ExPASy) corresponding to the single 
tyrosine residue in Aβ 42.  Peptide integrity after SEC was again confirmed by MALDI-
ToF mass spectrometry, which showed a monoisotopic molecular mass of 4516.31 Da, in 
good agreement with a calculated mass of 4513.13 Da.  Monomeric Aβ 42 fractions were 
stored at 4°C and used within 2–5 days of SEC purification in all experiments to avoid 
any preformed aggregates in our reactions. 
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Thioflavin Fluorescence Spectroscopy (ThT Fluorescence)  
 ThT fluorescence assays were performed as previously reported.5  Briefly, 5 µL 
aliquots of reactions were diluted with 70 mL of 10 µM ThT in 20 mM Tris, pH 8.0 in a 
quartz microcuvette.  ThT fluorescence was performed by exciting at 450 nm and 
monitoring the emission at 482 nm in kinetic mode for 1 min with excitation and 
emission slits were set at 10 nm.  
Polyacrylamide Gel Electrophoresis (PAGE) 
 Samples were dissolved in loading buffer (1X Laemmli buffer) containing 1% 
sodium dodecyl sulfate (SDS), applied without heating to 4–20% Mini-PROTEAN TGX 
gels (Biorad) containing bis-Tris, and resolved in Laemmli running buffer with 0.1% 
SDS.  Dye-linked molecular mass markers (Blue Plus2 Prestained Standards, Invitrogen) 
were run in parallel for calibration.  Gels were visualized using a silver stain kit (Pierce) 
following standard protocols provided from the manufacture.  
Results and Discussion 
Monomer and Polymer Synthesis  
 AcGlcEAm and AcGalEAm glycomonomers were synthesized using a 
modification of the procedure reported by Ambrosi et al.16 as described in the 
experimental section and illustrated in Scheme 1.  We chose to synthesize acrylamide-
based glycomonomers, rather than the methacrylate monomers studied by Ambrosi et al., 
to take advantage of their ready polymerization in aqueous solution under moderate 
reaction conditions, hydrolytic stability, solubility over a range of pH and salt 
concentrations, and relatively simpler purification.  In our system, silver triflate was 
substituted for silver carbonate in the traditional Koenigs-Knorr reaction.  The reactions 
  
were performed at room temperature over a period of 
removed through acid washes, leaving the saccharide functionalized acrylamide, 
AcGalEAm and AcGlcEAm, in the organic layer
70%).  In the Ambrosi methacrylate system, on the other hand, 
increased reaction time of 48 hrs, and product purification by column chromatography 
were required.  They polymerized protected and deprotected monomer and conc
that deprotection of the monomer prior to polymerization resulted in better removal of the 
acetyl groups.  Due to the increased hydrolytic stability of the amide linkage in our 
acrylamide system, concern over the decomposition of the monomer during d
was eliminated.  Sodium methoxide
groups, and complete deacetylation occurred without loss of product (
To our knowledge, this is the first report of the synthesis of an acr
with a specific attachment at the C1’ carbon of either glucose or galactose.
Figure 3. 1H NMR, in deuterated chloroform, of AcGalEAm, with proton peaks assigned.
 
 
24 hours and excess HEAm was 
 (1H NMR in Figures 3 
-40°C reaction conditions, 
 in methanol was used to remove the acetyl protecting 
Figures 
ylamide glycomonomer 
20 
and 4, yield 
luded 
eprotection 
5 and 6).  
 
 
 
  
Figure 4. 1H NMR, in deuterated chloroform, of AcGlcEAm, with proton 
Figure 5. 1H NMR, in deuterated water, of GalEAm after de
assigned. 
 
Figure 6. 1H NMR, in deuterated water, of GlcEAm after de
assigned. 
 
 
-protection with proton peaks 
-protection with proton peaks 
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peaks assigned. 
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 Confirmation of the stereochemistry at the C1’ carbon was achieved through 1H 
NMR analysis.  Bubb et al. identified the proton peaks correlating to the α and β 
enantiomers for glucose modified at the C1’ carbon.21  With this knowledge and a 
1HNMR of enantiomeric D-glucose and D-galactose, identification of the proton peaks 
correlating with the α- and β-enantiomers of synthesized monomers was easily 
determined.  Figure 7 shows 1HNMR spectra of D-galactose (upper) and GalEAm 
(lower), where the peak for the α-enantiomer for galactose appears around 5.0 ppm and 
the β-enantiomer proton peak is located around 4.20 ppm.  Figure 8 shows a similar 
comparative spectrum for D-glucose and GlcEAm.  Integration of the α and β proton 
peaks for GalEAm (Figure 7) and GlcEAm (Figure 8), showed that 98% and 88%, 
respectively, of the monomers had the desired β orientation at C1’.  It is possible that the 
GlcEAm showed less stereochemical control than the GalEAm because of neighboring 
group effects in glucose, which has the C4’ hydroxyl group equatorially positioned and 
may sterically affect the β-enantiomer.    
  
 
Figure 7. Representative
(upper) as compared to synthesized GalEAm (lo
desired β-linkage. 
 
 
 
 
 
1H NMR showing C1’ stereochemistry of stock D
wer), where GalEAm has 98% of the 
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-galactose 
  
Figure 8. Representative
(upper) as compared to synthesized GlcEAm (lower), where GlcEAm has 88% of the 
desired β-linkage. 
 Four homopolymers of GalEAm and GlcEAm at differing molecular weights and 
copolymers of DMA with GalEAm and GlcEAm were synthesized via aRAFT 
polymerization, following the reaction procedure outlined in 
summary of the theoretical
spectra of PGal300, PGlc300
of the monomers are no longer present and are replaced by methylene peaks of the 
polymer backbones at 1.0 
unique peaks of d’, e’ (2.8 ppm) for DMA and d, e, g, h,
GalEAm and GlcEAm (Figures 
determine the mol% of monomers in each copolymer. As indicated in 
 
 
 
1H NMR showing C1’ stereochemistry of stock D
Scheme 3.  In 
 MWs.  Figures 9, 10, 11 and 12 are representative 
, PDMAGal300 and PDMAGlc300, respectively. The vinyl peaks 
- 2.0 ppm, indicating successful polymerizations. 
 i, j, k, l (3.0-3.9 ppm) for both 
11 and 12, respectively) were identified and integrated to 
Table 1
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-glucose 
Table 1 is a 
1H NMR 
 Furthermore, 
, 
  
incorporation for all monomers was close to the theoretical 
GlcEAm representing 37% and 32% of their respective copolymers. 
Table 1  
 
Summary of aRAFT polymerized glycopolymers
 
Polymer 
1. PGal
300 
2. PGal
30
 
3. PGlc
300
 
4. PGlc
30
 
5. PDMAGal300 
6. PDMAGlc300 
 
aTheoretical calculations based upon [M
 
DMA and 39 mol% GlcEAm. 
 
Figure 9. Representative 
 
 
prediction, with GalEAm and 
 
 
Mn
th
(g/mol)a mol% Sugar
88,000 
8,500 
79,000 
7,500 
50,700 
110,200 
o]/[CTA]. bTheoretically, 56 mol% DMA and 44 mol% GalEAm. cTheoretically, 61 mol% 
1H NMR, in deuterated water, of PGal300. 
25 
exp 
100 
100 
100 
100 
37b 
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Figure 10. Representative
Figure 11. 1H NMR, in deuterated water, of PDMAGal
 
Figure 12. 1H NMR, in deuterated water, of PDMAGlc
 
 
 
1H NMR, in deuterated water, of PGlc300. 
300. 
300. 
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The controlled nature of the polymerization of the homopolymers and copolymers 
was confirmed through the linear, pseudo first order increase of ln(Mo/M) as a function 
of time (Figure 13), where Mo is the initial concentration of monomer and M is the 
monomer concentration at any given time point.  An initialization period was seen for all 
polymers (90 minutes for PGal30 and PGlc30, 30 minutes for PGal300 and PGlc300, and 
15 minutes for PDMAGal300 and PDMAGlc300).  Researchers attribute this 
initialization period to the time in which it takes for every CTA molecule to relinquish its 
R group and add a monomer unit.  This is not uncommon with less stable acrylamide 
radicals, as the CTA prefers to continue interacting with its more stable R group.22  As a 
result, a shorter inhibition period is observed for higher monomer to CTA ratios, as there 
are fewer CTAs that must add monomer.  DMA, appears to be a more stable radical than 
GalEAm and GlcEAm, adds more quickly to the CTA, resulting in a shorter initialization 
period for the copolymers.   
  
Figure 13. Kinetic plot of ln([M
PGal30, PGlc30 and c) PDMAGal
the polymerization followed a predictable controlled behavior.
 
 
0]/[M]) as a function of time for a) PGal300
300, PDMAGlc300. The linear relationship indicated that 
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Additionally, the rate of polymerization varied between the high and low MW 
homopolymers, the copolymers and the type of sugar monomer present in each polymer, 
as seen in Figure 13a-c.  Across all MWs and polymer compositions, the rate of reaction 
was faster for polymers with GalEAm, as opposed to GlcEAm. It is currently not 
understood why monomers that differ at only one stereocenter (C4’) would display 
different reaction rates.  The rate of reaction was also faster for the lower molecular 
weight polymers (PGal30 and PGlc30), as compared to the higher molecular weight 
polymers (PGal300 and PGlc300). This is attributed to the greater number of radicals 
present in the lower molecular weight systems.23  Statistical copolymerization of DMA 
with GalEAm and GlcEAm resulted in an increase in the rate of polymerization as 
compared to both MWs of sugar homopolymers.  
Evaluation of Aβ aggregation in the presence of glycopolymers 
Aβ aggregation was evaluated by ThT fluorescence and SDS-PAGE.  In Figure 
14, ThT fluorescence emission spectra as a function of incubation time for Aβ monomer 
incubated alone (control) and with DP 300 and DP 30 galactose and glucose 
glycopolymers, respectively, is shown.  An increase in intensity indicates the presence of 
hydrophobic association of ThT with the molecules.  For the Aβ control sample, a 
characteristic sigmoidal curve is exhibited, which is associated with formation of 
oligomers that associate to eventually form fibrillar structures.  The lag time, or the time 
before increase in fluorescence associated with aggregation is observed, was shorter for 
DP 300 PGal than for the Aβ control, showing increased ThT fluorescence at 24 hrs.  
PGal and PGlc, with DP 30, and PGlc300 increase the lag time of aggregation to 72 hours.  
For the high molecular weight PGal300 and PGlc300 glycopolymers, fluorescence intensity 
  
plateaus at around 3 a.u. and 1.5 a.u. after 24 and 72hrs, respectively, 
stabilized aggregate species is formed. 
increases the lag time, indicating a uniquely different association pathway for this system.  
ThT fluorescence for the PGal
from that of the control, while that of PGlc
not reach the level of the control solution until the final testing point at 144 hours. 
indicates that the presence of glucose glycopolymers alters the aggregation pathway.  At 
the final testing point of 144 hours,
the control show similar levels of fluorescence, indicating the presence of highly 
aggregated species.  The high molecular weight glycopolymer solutions, however, show 
constant low fluorescence levels in
Figure 14. ThT fluorescence emission 
PGlc300, and PGlc30 with A
 
 
suggesting that
 Notably, the PGlc300 sample dramatically 
30 solutions does not appear to be statistically different 
30 solutions is dramatically slower and does 
 the low molecular weight glycopolymer solutions and 
dicative of a different type of aggregation.   
intensity as a function of time for PGal
β 42, at a ratio of 1:3 (Aβ:polymer).   
30 
 a 
 This 
 
 
300, PGal30, 
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SDS-PAGE analysis was performed at 72 and 144 hours of incubation (Figure 
15).  The lane furthest to the left, labelled monomer control, shows a single band at 
around 3.5 kDA after 72 hours and no band after 144 hours, indicating that in the absence 
of glycopolymer the Aβ exists in the monomer or highly aggregated state (MW too large 
to enter the gel).  The PGal30 and PGlc30 lanes show bands at 3.5 kDA and light stains 
around 200 kDA at 72 hours of incubation, indicating that the Aβ in these solutions exist 
as monomers or high MW oligomers.  At 144 hours of incubation, the monomer band is 
lighter and the 200 kDA oligomer band is more clearly seen.  The Aβ solutions incubated 
with PGal300, at both time points, show bands at 3.5 and 13 kDA, and a diffuse, heavy 
band at 50-200 kDA, indicating the presence of monomer, low molecular weight 
oligomers, and high molecular weight oligomers of 11-44mer Aβ units that do not 
proceed to form fibrils within the tested period.  Aβ solutions incubated with PGlc300, 
however, show heavier bands at 13-18 kDA, which correlate to 3-4mer Aβ units, as well 
heavy diffuse bands corresponding 11-44mers from 50 – 200 kDA.  For the PGlc300 the 
monomeric Aβ is not present at 72hrs, in contrast to the other environments tested, 
indicating that PGlc300 quickly causes the formation of oligomers.  This is significant as 
the smaller 3-4mer Aβ units are thought to be the most toxic form of Aβ.5, 20 
  
 
Figure 15. SDS-PAGE of A
galactose glycopolymers of DP 30 and 300.
stain and do not appear on the gels.
These results confirm that galactose
directly influence the aggregation of A
effects of gangliosides on A
oligomeric aggregates that resemble proto
formation of smaller toxic oligomers.
Glucose and galactose glycomonomers, with an acrylamide backbone, were 
synthesized, maintaining control over the stereochemistry at the C1’ ca
 
 
β aggregates that resulted from incubation with glucose and 
 Glycopolymers are not affected by silver 
 
- and glucose-containing glycopolymers 
β, and provide an indication of the expected 
β aggregation.  Both systems promote the formation of large 
-fibrils, while glucose also promotes the 
 
Chapter Summary 
rbon. 
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polymerized with DMA via aqueous RAFT to produce homopolymers and copolymers of 
precise molecular weights.  Interestingly, different reaction kinetics were observed for the 
two sugar monomers, GalEAm and GlcEAm, as well as for the various homopolymers 
and copolymers.  Specifically, GalEAm reacts much faster than GlcEAm and the lower 
MW polymers react faster than the higher MW polymers.  Aggregation kinetics and 
aggregate size of Aβ in the presence of high and low MW glycopolymers were evaluated.  
Aβ incubated with the PGal300 and PGlc300 remained at aggregation sizes attributable to 
oligomers, with PGlc300 promoting smaller oligomers (3-4mer) that are potentially more 
toxic.  PGal300 also reduced the time required for initial aggregation (lag time). Glucose 
and galactose glycopolymers with DP 30 increased the lag time of aggregation but 
ultimately do not impede fibril formation.  We report a new platform for synthesis of 
glycopolymers of controlled architecture which can accommodate a range of biologically 
relevant saccharides for evaluation of Aβ aggregation pathways in the presence of 
polysaccharide interfaces.   
Recommendation for Future Work 
 Isolation of oligomeric species, resulting from incubation of Aβ monomer with 
PGlc300, would be an important next step in this project.  This would allow for 
determination of the stability of the oligomeric species, identifying if the aggregation 
process is “on” or “off” pathway, as described by Kumar et al.20  Additionally, it would 
allow for conformational analysis of each oligomeric species through circular dichroism 
(CD).  It is currently assumed that the aggregates have formed β-sheets; however, CD 
must be done to confirm.  
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 The control provided by RAFT polymerization of acrylamide based 
glycopolymers could also allow for the investigation of other saccharides, such as N-
acetyl-D-galactosamine, that are present in GM1 gangliosides, as an incomplete 
understanding of the GM1 ganglioside head group has been obtained.  An alternative 
monomer synthesis would need to be utilized.  Namely, β-alanine would be reacted with 
acyl chloride, under anhydrous conditions, in order to synthesize an acrylamide monomer 
with a pendant carboxylic acid.  Subsequently, N-acetyl-D-galactosamine, using N,N'-
dicyclohexylcarbodiimide coupling, could be added to the pendant carboxylic acid.  
aRAFT polymerization, using the previously described conditions, could then be done to 
obtain multiple MWs of the galactosamine monomer, which would then allow for a 
comparative study of Aβ aggregation.  
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CHAPTER IV 
ANTIMICROBIAL PEPTIDE MIMICS AND BACTERIAL INTERFACE 
Chapter Overview 
 This chapter aims to inform the reader of pertinent literature pertaining to 
antimicrobial peptides and antimicrobial peptide mimics, providing the argument and 
need for the research presented in Chapter V.  Specifically, naturally occurring 
antimicrobial peptides (AMPs) display the ability to eliminate a wide variety of bacteria, 
without toxicity to the host eukaryotic cells.  Synthetic polymers containing moieties 
mimicking lysine and arginine components found in AMPs have been reported to show 
effectiveness against specific bacteria, with the mechanism of activity purported to 
depend on the nature of the amino acid mimic.  In an attempt to incorporate the 
antimicrobial activity of multiple amino acids in a single water soluble copolymer, a 
series of copolymers containing lysine mimicking aminopropyl methacrylamide (APMA) 
and arginine mimicking guanadinopropyl methacrylamide (GPMA) were prepared via 
aqueous RAFT polymerization.  Copolymers were prepared with varying ratios of the 
comonomers, with degree of polymerization of 30 and narrow molecular weight 
distribution to simulate naturally occurring AMPs.  Antimicrobial activity against Gram 
negative and Gram positive bacteria, and selectivity via hemolysis of red blood cells and 
MTT assays of MCF-7 cells, were determined.  It was found that broad spectrum 
antimicrobial effectiveness, including Pseudomonas aeruginosa, was obtained for 
polymers with high levels of APMA, with low toxicity toward eukaryotic cells. 
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Important Literature 
 Antimicrobial peptides (AMPs) are naturally occurring defensive agents that 
eliminate a wide range of bacteria and are found in a variety of eukaryotic organisms, 
including mammals, insects, and plants.  Over 500 unique AMPs are catalogued.24  
Researchers believe that specific environmental needs influence the composition of 
AMPs.  However, these peptides display several consistent characteristics, including a 
composition of 20-50 amino acid residues, distinct hydrophobic and hydrophilic regions, 
and a net positive charge at physiological pH (7.4).  The hydrophilic regions have an 
abundance of lysine and arginine amino acid residues, which are protonated and 
positively charged under physiological conditions.  It is this net positive charge that 
enables AMPs to selectively bind to bacteria, as their membranes are negatively charged, 
and induce cell death.  The host eukaryotic cells have a net neutral charge and, therefore, 
do not have as high an affinity for AMPs, resulting in an efficient and selective defense 
against bacteria.  
 AMPS are of interest because bacteria do not appear to develop resistance to 
AMP activity as readily as they do against current synthetic antibiotics.  Unfortunately, 
isolation or synthesis of sufficient quantities of AMPs is difficult and costly.  Polymeric 
mimics of AMPs are a desirable alternative because they have the potential to be 
produced at reduced cost and are easier to synthesize.25  
 Several parameters are known to affect the efficacy of successful AMP mimics.  
First, polymers of lower molecular weight, around that of natural AMPs, show greater 
antimicrobial activity than monomers or higher molecular weight systems.26  Second, the 
amphipathic balance of the polymer mimic is essential for optimal antibacterial activity 
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as well as selectivity.  Polymeric AMPs that are too hydrophobic reduce selectivity and 
result in eukaryotic cell death.  A number of different methods have been employed to 
modify the amphipathic balance in synthetic systems.  Researchers increased 
hydrophobicity through copolymerization of hydrophobic monomers with alkyl tails of 
different lengths with cationic comonomers, which generally resulted in increased 
bacterial cell death at the expense of selectivity.27  Multiple polymer backbone structures, 
including methacrylates,27a, 27b, 28 β-lactams,29 norbornenes,30 and methacrylamides27c, 31 
with varying solubility and inherent polarity have been evaluated as AMP mimics.  
Palermo et al. showed that methacrylamide based AMP mimics, due to the increased 
polarity of the amide, had a decreased toxic impact on red blood cells as compared to 
similar methacrylate based polymers. 27c, 28a  These methacrylamide polymers also 
demonstrated increased antimicrobial activity, as the more soluble backbone allowed 
complete protonation, and, therefore, increased charge density, of the primary amine 
cationic moiety.  
 The choice of cationic moiety also impacts the effectiveness of synthetic AMP 
mimics. Mostly primary amines,27b, 29-30, 31 which mimic lysine amino acid residues, have 
been employed; however, tertiary31 and quaternary28a amines have  also been 
investigated.  Results indicate, however, that transition from primary to tertiary or 
quaternary amines reduces activity and selectivity of AMPs. In our previous work, we 
investigated the effect of pendant cation modification with various alkyl groups to alter 
the amphipathic ratio of methacrylamide AMPs, and found that unmodified primary 
amine cations display superior antimicrobial activity and selectivity.31  Researchers have 
also begun to explore guanidinium, which mimics arginine amino acid residues found in 
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natural AMPs, as an alternative cationic moiety.  Gabriel et al., using a polynorbornene 
backbone, reported that substituting guanidinium for primary amines improved selectivity 
without affecting the antimicrobial activity.30b  Locock et al., using a methacrylate 
backbone, reported that guanidinium improved both activity and selectivity.28b  
  Naturally occurring AMPs demonstrate different mechanisms of bacterial cell 
death based on the prevalence of lysine or arginine in the peptide.  The two principal 
mechanisms are (1) cell penetration, which correlates with a predominance of arginine, 
and (2) membrane disruption, which correlates with an increased occurrence of lysine.24, 
32
  Similarly, guanidinium based AMP mimics appear to kill bacterial cells in a manner 
that differs from that of primary amine based AMP mimics.  Specifically, guanidinium 
functionalized polynorbornenes did not demonstrate the bacterial membrane disruption 
behavior observed in primary amine functionalized polynorbornenes, suggesting that cell 
death proceeded via an alternate mechanism.33  Locock and coworkers reported that 
increasing the molecular weight of their guanidinium AMP mimics resulted in reduced 
antimicrobial activity, while the antibacterial effectiveness of primary amine AMP 
mimics was less sensitive to changes in molecular weight over the range tested.  These 
findings suggest the possibility of improving antimicrobial properties by incorporating 
both lysine and arginine mimics in synthetic AMPS, which should provide the ability to 
kill bacteria through different mechanisms and be effective against a wider selection of 
bacteria.   
 Treat and coworkers investigated the viability of poly(3-guanidinopropyl 
methylacrylamide) copolymers as cell penetrating vehicles for potential drug delivery 
applications.  They found that significant amounts of polymer were taken into the 
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eukaryotic KB cell through endocytotic and passive pathways.34  These results indicate 
the potential reduction in selectivity for guanidinium-containing AMP mimics, and 
suggest the need for further study of the effectiveness of the systems.  Investigation into 
the effect of counterion type on antimicrobial activity is also needed.35  Previous reports 
have separately employed TFA or Cl counterions with gauanidinium moieties; however, 
to our knowledge, the effects of counterion structure have not been reported.28b, 30b  
Antimicrobial activity of AMP mimics has been tested against both gram-positive 
bacteria, which have a cell wall that surrounds an inner plasma membrane, and gram-
negative bacteria, which have a thin cell wall that is sandwiched between two plasma 
membrane layers.  Typically, E. coli, Gram-negative, and B. subtilis, Gram positive, are 
used as representative bacteria in antimicrobial activity testing.  However, to our 
knowledge, the effects of synthetic AMPs on Pseudomonas aeruginosa, which displays 
an inordinate ability to resist traditional therapeutics and is the most reported nosocomial 
bacterium,36 have not yet been evaluated.  Staphylococcus aureus, due to the emergence 
of methicillin resistant strains, is also of great concern.  
In this study, statistical copolymers of aminopropyl methacrylamide (APMA) and 
3-guanadinopropyl methacrylamide (GPMA) of controlled molecular weight and 
composition are prepared via aqueous RAFT polymerization for determination of the 
effects of lysine- and arginine-mimicking pendant groups in a fully water-soluble AMP 
mimic on antimicrobial activity and selectivity.  Polymers are prepared with molecular 
weights similar to those of naturally occurring AMPS, and the effects of counterion type 
are examined.  The low molecular weights of the synthesized polymers eliminate the 
need for built-in biodegradability, as small molecules are removed from the body via the 
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renal system.37  Under the benign aqueous RAFT reaction conditions, Boc-protection of 
the amine-containing monomers is not required.  
Antimicrobial behavior against E. coli, S. aureus, and P. aeruginosa, and 
selectivity testing via hemolysis of red blood cells and MTT assays of MCF-7 cells are 
reported.  Broad spectrum antimicrobial effectiveness coupled with low toxicity towards 
eukaryotic cells is observed for copolymers with high concentrations of the lysine-
mimicking APMA monomer.  
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CHAPTER V 
EXPERIMENTAL DETAIL FOR ANTIMICROBIAL PEPTIDE POLYMER MIMICS 
Research Overview 
Our ultimate goal is to investigate the effectiveness of guanidiniums moieties 
within our established methacrylamide based platform for AMP mimic development and 
tailoring via tuning of (co)polymer composition.  Attachment of guanidinium has 
previously resulted in improved activity and selectivity of AMP mimics.28b, 30b  This 
research aims to increase antimicrobial activity and selectiveness across a broader 
spectrum of bacteria through pairing of increased solubility of a methacrylamide polymer 
backbone and guanidinium pendant groups.  In this chapter, we describe a novel method 
for GPMA synthesis that allows for improved yield, simplified purification and handling. 
Additionally, a range of GPMA-stat-APMA copolymers were synthesized for the first 
time using aqueous RAFT polymerization, which allows for control over MW, narrow 
PDI and benign reaction conditions.  Polymerization, due to the benign reaction 
conditions, did not require Boc-protection of APMA or GPMA.  Antimicrobial behavior 
against E. coli, S. aureus, and P. aeruginosa, which to the best knowledge of the author 
has never been reported in polymeric AMP papers, was performed, and selectivity testing 
via hemolysis of red blood cells and MTT assays of MCF-7 cells was done.  As before, 
the low molecular weights of synthesized polymers eliminates the need for built in 
biodegradability, as small molecules can be removed from the body via the renal 
system.37 
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Objectives of Research and Research Questions 
I. Synthesize statistical copolymers of APMA and GPMA via aqueous RAFT 
polymerization to expand upon our previous polymeric AMP platform and enable 
a systematic evaluation of the effect of pendant guanidinium cations. 
a. Is APMA and GPMA able to be statistically synthesized via aqueous RAFT 
polymerization?  
II. Determine the antimicrobial activity and selectivity of synthetic AMP mimics as a 
function of the polymer guanidinium content and counterion identity. 
a. Does the addition of guanidinium increase the antimicrobial activity of 
synthesized AMPs over a broader range of bacteria? 
b. Is there indication of an alternative bacterial death mechanism with the 
incorporation of guanidinium? 
Materials and Methods 
Materials 
For GPMA synthesis, N-(3-aminopropyl) methacrylamide hydrochloride, >98% 
(APMA·HCl) (Polysciences, Inc.), triethylamine, >99.8% (TEA) (Sigma-Aldrich, USA), 
N, N’-di-boc-1H-pyrazole-1-carboxamidine (PCA) (Sigma-Aldrich, USA), acetonitrile, 
anhydrous, 98% (Sigma-Aldrich, USA), sodium sulfate (Sigma-Aldrich, USA), 
trifluoroacetic acid (TFA) Sigma-Aldrich, USA) and 4M HCl in dioxane (Fischer 
Scientific, USA) were used as purchased.  For all polymerizations, 4, 4’-Azobis (4-
cyanopentanoic acid) (V-501) (Sigma-Aldrich, USA), methanol, anhydrous, 99.8% 
(Fischer Scientific, USA), sodium acetate, anhydrous (Sigma-Aldrich, USA), acetic acid, 
glacial (Fisher Scientific, USA) and Spectra/Por® dialysis membrane, standard RC 
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tubing (3,500 kD) (Spectrum Laboratories, Inc.,  were used as purchased.  4-cyano-4-
(ethylsulfanylthiocarbonylsulfanyl)pentanoic acid (CEP) was used as the CTA in all 
polymerizations and was synthesized via previously published procedures.18  For 
antimicrobial susceptibility testing, Escherichia coli (ATCC), Staphylococcus aureus 
(ATCC), Pseudomonas aeruginosa (ATCC), Mueller-Hinton broth (MHB) (Fischer 
Scientific) and low salt Luria Broth (10 g/L tryptone, 5g/L yeast extract, 0.5 g/L NaCl) 
(LB) (Sigma-Aldrich, USA) were used as purchased.  Tris (hydroxymethyl) 
aminomethane (Tris) (Sigma-Aldrich, USA) and NaCl (Sigma-Aldrich, USA) were used 
to make tris-buffered saline (TBS) (10 mM Tris, 150 mM NaCl, pH 7.4).  All selectivity 
testing was done with Triton-X 100 (Merck, India), Dulbecco’s Modified Eagle Media 
(DMEM) (Himedia, India), fetal bovine serum (FBS) (Himedia, India), Trypsin-EDTA 
Solution 1X (Himedia, India), antibiotic solution 100X Liquid (AS) (made with penicillin 
and streptomycin) (Himedia, India), (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, India) and dimethyl sulfoxide 
(DMSO) (Merck, India), and used as received.  Preparation of MCF-7 cells (NCCS, 
Pune, India) is discussed in the cell viability section of this paper. Isolation of red blood 
cells (RBC) (AIIMS hospital, New Delhi, India) is discussed in the hemolysis section of 
this paper.   
Synthesis of Boc-protected GPMA 
APMA·HCl, dissolved in a mixture of DI water (12 mL) and TEA (20 mL, 148 
mmol), was stirred at 25°C. PCA (10 g, 32 mmol), dissolved in acetonitrile (108 mL), 
was then added drop-wise, over 30 minutes, to the stirring APMA·HCl solution via an 
addition funnel (Scheme 4).  The reaction progressed for 24 hr.  The product was purified 
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via filtration, washed three times with DI water (50 mL) and lyophilized overnight (yield: 
91%).  1H NMR (300 MHz, CDCl3): δ [ppm] 1.46 and 1.50 (d, H-G); 1.70 (m, H-D); 
2.00 (s, H-C); 3.32 (m, H-F); 3.49 (m, H-E); 5.31 (s, H-A); 5.81 (s, H-B); 7.39 (t, H-H); 
8.49 (t, H-I); 11.53 (s, H-J). 
 
Scheme 4. Synthesis of Boc-protected GPMA. 
Deprotection of Boc-protected GPMA 
Deprotection of GPMA proceeded in one of two ways in order to alter the 
counterion coordinated to the guanidinium, as the conjugate base of the acid used to 
deprotect becomes the counterion.  First, Boc-protected GPMA (10.96 g, 28.48 mmol) 
was dissolved in CH2Cl2 (90 mL), stirring at 0°C. TFA (87 mL, 1.14 mol) (20 eq. per 
boc-protecting group) was then added to the solution drop-wise via an addition funnel 
and the reaction was allowed to progress for 16 hours, while gradually warming from 0°C 
to 25°C (Scheme 5).  The solvents were removed via rotary evaporation and the resulting 
clear viscous oil was dissolved in 250 mL DI H2O, frozen in liquid N2, and lyophilized 
for 48 hr.  The product was obtained as a white solid.  Second, Boc-protected GPMA was 
dissolved in 4M HCl in dioxane (7 eq. per boc-protecting group) and allowed to react 
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overnight.  The product, a white solid, precipitated from solution and was purified via 
filtration and washing with anhydrous dioxane.  1H NMR (300 MHz, DMSO): δ [ppm] 
1.65 (m, H-D’), 1.86 (s, H-C’), 3.13 (m, H-E’, F’); 5.34 (s, H-A’); 5.66 (s, H-B’); 7.27 (s, 
broad, H-H’, I’); 7.70 (t, H-J’); 8.00 (t, H-K’).  
 
Scheme 5. Deprotection of Boc-protected GPMA with either TFA or HCl, which alters 
the resulting counterion for deprotected GPMA. 
Polymerization of Antimicrobial Peptide (AMP) Mimics 
Utilizing aqueous RAFT polymerization, polymer molecular weights were 
targeted by selecting appropriate initial monomer and CTA concentrations.  The ratio of 
M0:CTA0 was set to be approximately 30:1 to yield a degree of polymerization of ~30, 
which mimics the size of naturally occurring AMPs.  4, 4’-Azobis (4-cyanopentanoic 
acid) was used as the initiator.  For all polymerizations, CTA0/I0=5.  The polymerization 
was conducted in aqueous acetate buffer (1.5 M sodium acetate and 0.5 M acetic acid, pH 
5) at 70°C19 for 6 hr (Scheme 6).  Methanol was added in low quantities (~30%) to 
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improve the solubility of CEP in the aqueous media.  After the reactions were completed 
the solutions were exposed to air and quenched in liquid nitrogen.  The solutions were 
then dialyzed against water for 72 hours, lyophilized for 72 hours, and then stored in 
desiccant until subsequent testing (representative yield: 75%).  Some polymer was lost in 
dialysis due to excessive swelling of the dialysis tubing as a result of internal osmotic 
pressure.  This loss can be minimized by making the water slightly acidic during the 
dialysis procedure to reduce the extent of swelling. 
The mol % of GPMA was varied to produce nine homo- and co-polymers.  The 
nomenclature PGT represents polyGPMA and the corresponding number indicates the 
targeted mole fraction in the (co)polymer.  For example, PGT25 represents a copolymer 
composed of 25 mol% GPMA·TFA and 75 mol% APMA·Cl.  The addition of either ·Cl 
or ·TFA indicates which counterion was coordinated with GPMA when it was 
polymerized. 
 
Scheme 6. Aqueous RAFT polymerization of poly(APMA-stat-GPMA) with either TFA 
or Cl as the counterion for GPMA. 
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Nuclear Magnetic Resonance (NMR) 
1H NMR was performed with a Varian MercuryPLUS 300 MHz spectrometer in 
CDCl3 and DMSO, utilizing delay times of 5 s to determine monomer purity.  A 500 
MHz NMR equipped with a standard 5 mm 1H/13C probe and operating at 499.77 MHz 
(1H) was used to identify the structures of PAPMA and PGPMA homopolymers and the 
structures of the poly(APMA-stat-GPMA) copolymers, with counterions of -TFA and -Cl, 
in D2O. 64 scans were taken for each experiment with a 3.1 second recycle delay.  For 
each of the homopolymers, unique peak assignments were made, and the copolymer 
compositions were calculated for the statistical polymers via peak integration of 
methylene bridge E and E’ on the APMA and GPMA monomer residues, respectively. 
The polymerization reaction progress was monitored, and the controlled nature of 
the reaction was ensured for PGT50·TFA through aliquots that were taken every hour 
from the reaction vial.  1H NMR was utilized to determine [M] at time (t) by comparing 
the vinylic hydrogen peak integrations to the integration of an internal standard (MeOH).   
Aqueous Size Exclusion Chromatography 
The molecular weight and polydispersity index (PDI) of the polymers were 
determined by aqueous size exclusion chromatography (ASEC) coupled with multi-angle 
laser light scattering (MALLS).  Eprogen CATSEC columns (100, 300 and 1000 Å) were 
used in combination with a Wyatt Optilab DSP interferometric refractometer (k = 690 
nm) and a Wyatt DAWN DSP MALLS detector (k = 633 nm).  1 wt% acetic acid/ 0.1 M 
Na2SO4 (aq) was used as the eluent at a flow rate of 0.25 mL/min.  The interferometric 
refractometer was utilized off-line to determine dn/dc values for PAPMA and PGPMA at 
25 °C in the eluent (1 wt% acetic acid/ 0.1 M Na2SO4 (aq)) in order to assign absolute 
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molecular weight values to all homopolymers.  For the statistical polymers the dn/dc 
values were calculated as the mole-fraction-averaged composites of the measured 
homopolymer dn/dc values using the copolymer compositions determined by 1H NMR.  
Wyatt ASTRA SEC/LS software was used for molecular weight and PDI calculations. 
ASEC-MALLS was also utilized to monitor molecular weight as a function of time.  The 
refractive index (RI) response vs elution volume, for aliquots taken at each time interval, 
was collected. 
Antimicrobial Susceptibility Assay 
Antimicrobial susceptibility was measured using the broth microdilution method 
according to the CLSI guidelines.38  Bacterial strains were incubated in MHB and all 
measurements were performed in triplicate.  Two-fold serial dilutions of each 
antimicrobial peptide mimic solution (1000 µg to 15.6 µg /ml) were prepared in a 96 well 
Costar® microtiter plate.  The microtiter wells were then inoculated with 5 × 105 colony 
forming units per ml of each test strain.39  After overnight incubation at 37°C, wells were 
analyzed for bacterial growth by measuring OD580 using a plate reader.  MHB without 
any peptides was also inoculated with each strain and used as a positive control for 
microbial growth.  Sterile MHB was used as a negative control and as a blank for 
absorbance readings.  The lowest concentration (µg/ml) of the peptides that completely 
prevented bacterial growth was considered the minimum inhibitory concentration (MIC).  
Additionally, antimicrobial susceptibility was tested using a procedure developed 
by Paslay et al.31  Namely, bacteria were grown overnight in low salt LB and then diluted 
to 0.001 OD600.  Polymer solutions, in TBS at concentrations of 70, 150, 230 and 300 
µg/mL, respectively, were incubated in a 96 well plate overnight at 37°C, with an equal 
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volume of the diluted bacterial suspensions.  Subsequently, the optical density of each 
well was measured using a UV-Vis plate reader to determine the level of bacterial growth 
in comparison to the positive and negative standards. 
Hemolysis Assay 
Hemolysis testing was done in accordance with the procedure previously 
published by Paslay et al.31  Whole blood was received from AIIMS hospital in New 
Delhi, India, requiring processing in order to isolate red blood cells (RBC).  The whole 
blood was centrifuged at 1500 rpm for 10 min, resulting in a RBC plug at the bottom of 
the centrifuge tube. Undesired serum was decanted, leaving the RBC plug. RBCs (30 µL) 
taken from the plug were suspended in TBS (10 mL) and then centrifuged at 1500 rpm 
for 10 min.  Suspension in TBS and centrifugation was repeated a total of three times to 
adequately rinse RBCs.  The final RBC solution consisted of rinsed RBCs suspended in 
TBS (10 mL).  Simultaneously, stock solutions at concentrations relevant to determined 
MICs of all homo- and copolymers were made using TBS.  
RBCs and polymers solutions were incubated together in micro-centrifuge tubes 
at a 1:1 ratio, with a total volume of 1 mL, at 37°C for 30 min.  The micro-centrifuge 
tubes were then centrifuged at 1500 rpm for 10 min to separate the intact, healthy RBCs 
from the rest of solution.  The supernatant, containing hemoglobin released from polymer 
lysed RBCs, was transferred to a 96-well plate (100 µL in triplicate) where absorbance at 
540 nm was determined in a Biotek PowerWave X S2 UV-VIS plate reader.  Percent 
hemolysis was determined through normalization of the observed absorbance for 
individual polymer wells to that of positive (100% hemolysis) and negative (0% 
hemolysis) controls.  
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MTT Assay 
Further selectivity testing was performed as previously described against MCF-7 
cancer cells.  Cells were grown to 80% confluence at 37°C in a 5% CO2 incubator, using 
tissue culture polystyrene flacon flasks and DMEM media that was supplemented with 
10% fetal calf serum and 1% antibiotic serum.31  Trypsin was added to dissociate cells 
from the flacon flask; cells were counted in a hemocytometer to determine cell 
concentration.  Fresh media was then added to the flacon flask so that cells could be 
seeded into a 96 well plate (100 µL per well).  Seeded cells were incubated for 24 hours 
at 37°C in a 5% CO2 incubator.  The old media was then removed from each well and 
replaced with fresh media (100 µL per well).  Polymer solutions (50 µL per well) were 
added to appropriate wells in triplicate, resulting in final polymer concentrations of 25, 
100, 200, 2000 µg/mL, respectively.  TBS (50 µL per well) and 3% Triton-X (50 µL per 
well) were added, in triplicate, as the positive and negative controls, respectively.  Plates 
were incubated for either 6 or 12 hrs at 37°C in a 5% CO2 incubator.  Old media was then 
removed and replaced with new media (100 µL per well).  MTT in TBS (10 mg/mL, 10 
µL per well) was added and allowed to incubate for 4 hrs at 37°C in a 5% CO2 incubator.  
Old media was removed and DMSO (100 µL per well) was added to dissolve formazan 
crystals produced by living MCF-7 cells.  Absorbance of each well was read at 570 nm 
using a Biotek PowerWave X S2 UV-VIS plate reader.  Percent cell viability was 
determined by normalizing the measured absorbance in polymer wells with the 
absorbance in the positive and negative control wells. 
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Results and Discussion 
GPMA Synthesis and (Co)polymerization 
Guanidinium functionalized synthetic AMP mimics were prepared to compare the 
broad-spectrum antimicrobial effectiveness of arginine and lysine analogues when 
incorporated as pendant groups into fully water-soluble, hydrolytically stable, 
methacrylamide copolymers (Scheme 7).  We previously demonstrated high selectivity 
and toxicity against E. coli (Gram-negative) and B. subtilis (Gram-positive) for lysine-
mimicking APMA polymers.  These findings combined with literature reports of 
antimicrobial effectiveness obtained with incorporation of guanidinium moieties in other 
polymeric systems,28b, 30b and the McCormick group’s previous copolymer reports of 
GPMA synthesis,34 provided the motivation for the current study.  Methacrylamide based 
monomers were chosen for their previously demonstrated antimicrobial activity and 
selectivity, hydrolytic stability, high degree of water solubility, and pKa values (ensuring 
ionization at physiological pH).   
  
Scheme 7. APMA (b) and GPMA
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TFA or HCl.  This allowed production of GPMA monomers at quantitative yield with 
counterions of different bulkiness and binding affinities.  
Table 2 
Molecular weight and composition data for GPMA synthesized (co)polymers. 
 
Polymer 
mol % 
GPMA 
(theory) 
mol % 
GPMA 
(exp)a 
Mn,th 
(g/mol)b 
Mn,exp 
(g/mol)c PDI
c
 dn/dcd 
1. (PAPMA·Cl) 0 0 5,600 6,500 1.06 0.200 
2. (PGT25·TFA) 25 23 6,500 6,900 1.03 0.183 
3. (PGT50·TFA) 50 45 7,400 6,100 1.06 0.169 
4. (PGT75·TFA) 75 72 8,300 5,800 1.12 0.152 
5. (PGT100·TFA) 100 100 9,200 8,100 1.04 0.132 
6. (PGT25·Cl) 25 30 6,500 7,000 1.11 0.183 
7. (PGT50·Cl) 50 44 7,400 7,400 1.12 0.169 
8. (PGT75·Cl) 75 67 8,300 8,100 1.16 0.152 
9. (PGT100·Cl) 100 100 9,200 9,200 1.11 0.132 
 
aDetermined by 1H NMR. bBased on 90% conversion of [M0]. cDetermined by ASEC-MALLS. dDetermined by a Wyatt Optilab  
DSP interferometric refractometer. 
GPMA copolymers of controlled molecular weight, narrow molecular weight 
distribution, and desired composition were prepared via aqueous RAFT polymerization 
as described in the experimental section (Table 2).  Measured values of molecular weight 
and GPMA incorporation are in good agreement with predicted values.  All polymers 
show narrow molecular weight distributions, with PDIs smaller than 1.2.  A plot of 
ln([M0]/[M]) for the polymerization of the 1:1 molar ratio of APMA:GPMA·TFA as a 
function of reaction time is linear (Figure 16), indicating pseudo first order kinetics and 
control of the polymerization.  Furthermore, GPC analysis (Figure 17) shows a steady 
  
increase in MW and narrowing of MWD as a function of reaction time, suggesting 
controlled polymerization.  
Figure 16. Poly(APMA-stat
function of time for the polymerization 
 
Figure 17. Poly(APMA-stat
function of reaction time 
APMA:GPMA·TFA. 
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 as a 
  
comparison of protons labelled E (2.8 ppm), from APMA, and E’ (3.0 ppm), from 
GPMA, and removal of proton contribution from D (3.0) are required.  E
integrated peaks indicates 45 mole % incorporation of GPMA into the copolymer
is close to the target composition
analyses were obtained for all copolymer compositions.  It was important to ensure that 
the targeted MW and copolymer composition were achieved 
effects of MW and MWD from those of polymer composition and counterion type on 
antimicrobial activity and selectivity. 
Figure 18. A representative 
(1:1 molar ratio of APMA:GPMA·TFA in feed).
Antimicrobial activity  
Broth microdilution testing
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For the copolymers providing 100% cell death in the therapeutic range (concentrations ≤ 
1000 µg/mL), MIC is tabulated in Table 3.  
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Figure 19. Broth microdilution results for all synthesized AMP mimics against (a) S. 
aureus, (b) E. coli, and (c) P. aeruginosa, where decreased absorbance correlates to 
increased bacterial death. 
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Table 3 
 
The minimum inhibitory concentration (MIC) determined from broth microdilution  
 
testing in Mueller-Hinton broth for the most effective AMP mimics 
 
 
MIC (µg/mL) 
Polymer S. aureus E. coli  P. aeruginosa 
1. (PAPMA·Cl) 1000 1000 1000 
6. (PGT25·Cl) - - 1000 
 
PAPMA·Cl demonstrated the greatest antimicrobial activity, providing 100% cell 
death for all three of the bacteria evaluated within the therapeutic range.  PAPMA·Cl’s 
effectiveness against P. aeruginosa is of particular significance because of this bacteria’s 
reported extreme resistance to traditional therapeutics.36  In general, antimicrobial activity 
decreased with increasing GPMA content, and only the copolymer with the lowest 
GPMA concentration (PGPMA25·Cl) showed 100% cell death within the therapeutic 
range.  Additionally, copolymers prepared with the TFA counterion showed lower 
activity than those associated with the chloride counterion.  This is attributed to the 
greater coordination and bulk of the TFA counterion, which effectively shields the cation 
and reduces interaction with the negatively charged bacterial membrane.  
Recognizing that the measured MIC value depends on the testing conditions, 
including media and broth type, buffer, and salt type and content,31 copolymer 
effectiveness was also evaluated in low salt LB against E. coli and S. aureus.  The results 
of these tests are found in Table 4.  In contrast to the findings observed in MHB, all 
copolymers show MICs in the therapeutic range against S. aureus and E. coli when tested 
in low salt LB.  This suggests that the decrease in salt content allowed increased 
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interaction of the AMPs with the bacterial membrane.  All copolymers appear equally 
effective against S. aureus, but the polymers with GPMA content greater than 75 mole % 
show greater effectiveness against E. coli in the low salt environment, even when paired 
with the TFA counterion.  The increased effectiveness of GPMA rich polymers against E. 
coli as opposed to APMA rich polymers, is attributed to mechanistic differences between 
the guanidinium and primary amine moiety in bacterial cell death.  The membrane 
disrupting mechanism of APMA requires a critical concentration to sustain a hole in the 
bacterial membrane and, thus, achieve MIC.32  The cell penetration mechanism of GPMA 
requires fewer units to translocate across bacterial membranes.40  
Table 4 
The minimum inhibitory concentration (MIC) determined from broth microdilution  
 
testing in low salt Luria broth 
 
 MIC (µg/mL) 
Polymer S. aureus E. coli 
1. (PAPMA·Cl) 300 300 
2. (PGT25·TFA) 300 300 
3. (PGT50·TFA) 300 300 
4. (PGT75·TFA) 300 150 
5. (PGT100·TFA) 300 70 
 
Thus, these results indicate that incorporation of GPMA into APMA polymers 
does not generally improve the antimicrobial activity.  APMA rich polymers and 
copolymers with chloride counterions show the most consistent antibacterial activity 
against the broadest range of Gram-positive and Gram-negative bacteria.  In a low salt 
environment, however, GPMA rich copolymers demonstrate increased effectiveness 
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against EC, which is attributed to mechanistic differences between guanidinium and 
primary amine moieties.  
Hemolysis Assay 
Selectivity testing against red blood cells (RBCs) was performed for all polymers 
at concentrations 50, 500, 1000 and 3000 µg/mL (Figure 20).  Hemolysis testing 
monitored the percent release of hemoglobin from RBCs as they lysed in comparison to a 
positive and negative control.  For all polymers, at all concentrations, RBC lysis is below 
10%, indicating low eukaryotic toxicity at desired antimicrobial concentrations (~1000 
µg/mL).  In general, hemolysis increases with polymer concentration, and the GPMA-
containing polymers show greater hemolysis than the PAPMA homopolymer.  Hemolysis 
also increases with increasing GPMA content.  This may be attributed to the lower 
polarity of the GPMA molecule in comparison to the APMA molecule.  No clear 
differences are observed for the copolymers prepared with TFA vs Cl counterions.  
 
Figure 20. Hemolysis testing, where % hemolysis of red blood cells as a function of 
relevant antimicrobial concentrations is shown for all synthesized AMP mimics. 
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MTT Assay 
The MTT assay utilized MCF-7 breast cancer cells as the representative 
eukaryotic cell for selectivity testing.  Figure 21 shows plots of % viability of MCF-7 
cells as a function of polymer concentration after incubation for six hours (a) and 12 
hours (b).  After six hours, greater than 70% cell viability is demonstrated for solutions of 
PAPMA homopolymer and PGT50 copolymers with both chloride and TFA counterions 
at concentrations up to 2000 µg/mL.  Exposure to the PGT homopolymers, however, 
results in dramatically reduced cell viability.  Similar results are observed after 12 hours 
of incubation, however the PAPMA homopolymer display slightly higher cell viability 
than the PGT50 copolymers.  No clear difference is observed for polymers produced with 
different counterions.  As in the hemolysis testing, the increased eukaryotic cell death 
caused by the GPMA polymers is attributed to their less polar character, in comparison to 
that of the APMA molecule.  
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Figure 21. MTT Assay for select AMP mimics, where % cell viability of MCF-7 cancer 
cells as a function of relevant antimicrobial concentrations is shown after incubation for 
(a) 6 hrs and (b) 12 hrs. 
Chapter Summary 
GPMA was synthesized and polymerized with APMA via aqueous RAFT to produce 
homopolymers and copolymers with narrow molecular weight distribution, DP of 30, and 
desired copolymer composition.  Antimicrobial activity was evaluated against Gram 
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negative E. coli and P. aeruginosa and Gram positive S. aureus.  Selectivity was 
evaluated via hemolysis and MCF-7 cell viability testing.  The PAPMA homopolymer 
demonstrated the greatest antimicrobial activity and selectivity of the copolymers 
evaluated, indicating its potential as a broad spectrum antibiotic.  Effectiveness against P. 
aeruginosa was particularly remarkable due to its resistance to traditional therapeutics.  
Only copolymers with a low concentration of GPMA showed antimicrobial activity in 
MHB, and GPMA copolymers with Cl counterion showed greater antimicrobial activity 
than those with TFA counterion.  When investigated in low salt LB, GPMA showed 
equivalent effectiveness against S. aureus and greater effectiveness against E. coli in 
comparison to that of APMA, demonstrating the salt sensitivity of the GPMA molecule.  
Eukaryotic cell death increased with increasing GPMA content.  Broad spectrum 
antimicrobial activity and selectivity were demonstrated for fully water-soluble, primary-
amine containing, methacrylamide polymers, without the need for incorporation of 
guanadinium adducts.  Evaluation of their effectiveness in preventing bacterial biofilm 
formation is underway.   
Recommendations for Future Work 
Synthesis of APMA and GPMA polymers with lower molecular weights is 
recommended.  This will, hopefully, decrease the concentration of polymeric AMP 
needed for complete cell death and allow for end groups investigation on antimicrobial 
activity and selectivity for PAPMA·Cl.  Namely, the effect of alkyl chains of varying 
lengths added at the carboxylic terminal of the polymer will be analyzed to investigate 
the hydrophobic impact of end groups on bacterial cell death.  Also, decreased molecular 
weight will, hopefully, allow PGT polymers to utilize the alternate bacterial cell death 
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mechanism supported in low salt LB and other works.  If effective antimicrobial activity 
is achieved after decreasing the MW of PGT polymers, the tunability of APMA and 
GPMA copolymers can then be better evaluated.  If altering the molecular weight of PGT 
polymers does not increase observed antimicrobial activity, incorporation of 
hydrophobicity through copolymerization of GPMA with monomers that have pendant 
aliphatic chains could be done to improve the hydrophilic/hydrophobic balance.  
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CHAPTER VI 
CONCLUSIONS 
 This work has utilized acrylamide based biomimetic polymers of specific 
architectures to evaluate (1) the impact of specific saccharides of GM1 ganglioside on the 
aggregation size and kinetics of Aβ monomers and (2) the antimicrobial activity and 
selectivity of lysine and arginine functionalities.  The key contributions from the first 
section are as follows: 
1. Synthesis of 2-(β-D-galactosyloxy)ethyl acrylamide (GalEAm) and 2-(β-D-
glucosyloxy)ethyl acrylamide (GlcEAm) as novel glycomonomers with 
attachment of the acrylamide backbone to the Cl’ carbon of the pendant 
saccharide predominately in the β-orientation, increasing the biological relevance. 
2. Polymerization of a series of GalEAm and GlcEAm homopolymers and 
copolymers with DMA, via aRAFT, to form a novel glycopolymer platform that 
has increased solubility and stability over a wide range of pH. 
3. Determination of aggregation kinetics and aggregate size of Aβ in the presence of 
glycopolymer. Low MW polymers of GalEAm and GlcEAm increased the lag 
time of Aβ aggregation as compared to Aβ incubated without glycopolymers but 
eventually resulted in highly aggregated species. High MW PGalEAm decreased 
the lag time and hindered Aβ aggregation from proceeding past high MW 
oligomers. High MW PGlcEAm increased the lag time and resulted in a mixture 
of high MW oligomer, low MW oligomer and monomer. Low MW oligomer is 
thought to be more toxic. Over all, the differences seen as a result of polymer 
MW indicate that a concentration of saccharide greatly influences aggregation 
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behavior. Additionally, the stereochemistry at the C4’ carbon, which is the 
difference between glucose and galactose, results in aggregation of species 
considered more toxic. 
The key contributions from the second section include: 
1. Improved synthesis of GPMA that allows for increased ease of production and 
yield.  
2. Expansion of our established acrylamide based antimicrobial peptide platform to 
include an arginine mimic, GPMA, as well as a lysine mimic, APMA. Well 
defined statistical copolymers of GPMA and APMA were polymerized via 
aRAFT to enable investigation of antimicrobial activity and selectivity of GPMA 
over a range of bacteria. 
3. PAPMA demonstrated the best antimicrobial activity in MHB, effectively killing 
E. coli, S. aureus, and P. aeruginosa which is particularly resistant to current 
therapeutics. Only statistical copolymers with low incorporation of GPMA and 
the Cl counterion were active in MHB. Use of low salt LB, showed that a high 
presence of GPMA in copolymers increased activity against E. coli. Broth type 
and counterion greatly impact GPMA due to the delocalization of charge across 
the guanidinium moiety. 
4. Selectivity testing against human red blood cells and cancer cells indicate that the 
synthesized polymers do not harm eukaryotic cells within relevant therapeutic 
concentrations. Polymers rich in GPMA were slightly more toxic due to 
delocalization of charge across the guanidinium moiety.     
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